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ABSTRACT 
Treatment of tumors with nanoparticles and combined drugs tend to turn effective as it can sustain for a longer time in the recipient’s body and 
also improve the impact. The conjugates that have proven to have high cytotoxicity are suggested in this report. Pegylation is an advanced drug 
delivery system that maximizes the immunity of the patient and helps in the correct targeting of the affected cells.  
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Drug delivery system is effective since long to treat patients 
with different disorders. The drug delivery methods have 
changed with the introduction of new technologies like 
nanotechnology1-3. Single and combined drug methodologies 
are used to overcome multidrug resistance and make the 
nanomedicine infusion process effective. This co-delivery is 
observed to offer the clinical advantage and improved 
efficiency thereby adding ease to the treatment of cancer 
patients4-8. This review paper begins with the conjugates 
that are used for single and combined drug delivery followed 
by the effectiveness of co-delivery therapy technique. The 
last section of the report discusses the applications of the co-
delivery method in the field of biomedicine.  
Conjugates for single and combined drug delivery 
The modern society has reported a high number of cases 
affected by cancer. Chemotherapy is a commonly used 
treatment for cancer. However, there are issues with the 
dosage and targeting. Camptothecin is one conjugate that can 
be used with the inhibitor and diluted with dimethyl 
sulfoxide. To build a self-assembly structure, camptothecin is 
conjugated with short oligo ethylene glycol. This can enable 
the patient to overcome drug resistance9-13.  
Similar to these conjugates, the nanoparticles that originate 
from the polymer self-assembly are highly effective. The end 
conjugate develops a spherical nanoparticle that has up to 8 
active drugs. In addition to camptothecin, disulfide bonding 
is used to crosslink with the nanoparticles and this act as a 
nano drug delivery system14-17. In some instances, paclitaxel 
and camptothecin are conjugated to develop a beta sheet 
forming multiple compounds and peptides. The advantage 
with this bond is that it self-assembles into nanostructures18-
21. This conjugate can release the cancer cause agents and 
eliminate cervical cancer cell from the body. This conjugation 
can also help overcome drug resistance.  
Not just restricted to the tumor, co-delivery can be a better 
option for treating breast cancer. Multiple polymers are 
combined and infused via the nanosized drug delivery 
system. Mitoxantrone is one anticancer agent that is already 
in use in the clinic since the past. Now, this is combined with 
covalent to improve efficiency22-25. Redox-triggered MTO 
prodrug performs a controlled drug release and improves 
the therapeutic effect. This amphiphilic MTO prodrug is a 
combination of MTO and TPGS where the micelles are self-
assembled26-29. 
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Figure 1: Schematic diagram of self-assembly, tumor targeting, redox-sensitive MTO release responding to the intracellular high 
level and inhibition of P-gp efflux of TPGS-based prodrug micelles 
 
This combination has brought better apoptosis promoting 
action. Further, the drug efflux rate is decreased, and drug 
resistance is controlled for the patient. When a single drug is 
induced, the patient does not see significant development. 
However, a co-therapy has multiple advantages with no 
accumulation of additional cancer or tumor-causing cells30-33.  
The effectiveness of co-delivery therapy 
Chemotherapy is often hindered due to the multidrug 
resistance problems faced by cancer patients. The cancer 
cells cannot tolerate the injuries induced by the drug. 
Therefore, there is a need for co-administration of various 
chemotherapeutic agents to be applied in the clinic4. It is 
observed that the co-delivery therapy for cancer is a 
promising mechanism as the undesirable toxicity is 
eliminated. Administration of the two drugs - fluorouracil 
and paclitaxel can improve efficiency in the treatment of 
MDR cancer34-38.  
There are multiple ways to enable co-delivery - inducing 
dual chemotherapeutic drugs, with MDR inhibitor and with a 
sensitizer. The MDR inhibitor is a combination of cytotoxic 
drugs and many efflux pump inhibitors. This combination 
can maintain cytotoxicity and improve pharmacokinetic 
properties. The most promising inhibitor is tariquidar as this 
can sensitize those resistant cell lines and control the 
overexpression of P-gp22,24,39,40.  
On the other hand, sensitizer compounds can fix the 
dysfunctional apoptotic signaling with chemotherapeutic 
drugs. Curcumin is yet another polyphenol that engages in 
anticancer activity and also down regulates the pathways 
from functioning and progressing the cancer cells further to 
other parts. It is observed that the co-delivery has a higher 
potential to control MDR and this only requires the proper 
selection of the nanotherapeutic delivery system to choose 
inhibitor/ sensitizer/ modulator9-11,37. 
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Pegylated drug delivery applications 
Drug delivery has now got different methods to reach the 
targeted cells and use inhibitors to control the activity of 
attacking molecule. Pegylation is a procedure where 
polyethylene glycol (PEG) (hydrophilic) is attached to the 
therapeutic molecule. This attachment improves 
hydrophilicity and also keeps up the activity of enzymes29,30. 
Pegylation typically includes hydroxyl groups, and PEG is 
attached to liposome/protein/peptide/polymersome. The 
application of PEG does not show high toxicity level. It has so 
far proved to be safe to the humans.  
The only drawback with this delivery system is the choice of 
molecules to influence the pharmacokinetics. Pegylation is a 
favorite technique to deliver drugs to the end body30. It is a 
model that is used in genetic engineering as well as several 
in vivo and in vitro applications. The other advantage with 
pegylation is that it can increase the half-life of vectors. As a 
result, the circulation times increases and the impact is 
longer. The concerned health problem is reduced. 
Conclusion 
The types of drug deliveries are numerous in the market. 
Nanomedicine is a field that encourages a play with 
nanoparticles to treat multiple health disorders. From the 
observation in this review sheet, it is known that co-delivery 
of therapeutic drugs can increase the effectiveness and the 
targeted delivery is feasible. The conjugate has to be chosen 
carefully. This drug delivery requires expert knowledge. 
Otherwise, it has a widespread application in the treatment 
of cancer and tumors and can be the future of the medical 
field.  
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